Form 10-Q AMARIN CORP PLC\UK For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Aegis Capital Comments on Amarin (AMRN) Following Q2 Results, Commercialization Update
August 8, 2014 9:23 AM EDTAegis Capital affirms its Buy rating and $2 price target on Amarin (Nasdaq: AMRN) following Q2 results.
Analyst Ram Selvaraju commented, [Amarin] recorded $12.6mm in Vascepa sales, below our estimate of $14mm. R&D expenses were $11.7mm, slightly above our forecast of $10mm, and SG&A expenses were $21.1mm, also above our projection of $18mm. While the firm reported earnings per share of $0.08 vs. our expectation of a... More
